These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8411030)

  • 41. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
    Shipman H; Flynn S; MacDonald-Smith CF; Brenton J; Crawford R; Tischkowitz M; ; Hulbert-Williams NJ
    J Genet Couns; 2017 Dec; 26(6):1280-1291. PubMed ID: 28540621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
    Baandrup L
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
    Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
    Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linkages among empathic behaviors, physical symptoms, and psychological distress in patients with ovarian cancer: a pilot study.
    Lobchuk MM; Bokhari SA
    Oncol Nurs Forum; 2008 Sep; 35(5):808-14. PubMed ID: 18765327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.
    Meiser B; Gleeson M; Kasparian N; Barlow-Stewart K; Ryan M; Watts K; Menon D; Mitchell G; Tucker K
    Gynecol Oncol; 2012 Jan; 124(1):153-7. PubMed ID: 22032838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A longitudinal study of psychological adjustment to familial genetic risk assessment for ovarian cancer.
    Ritvo P; Robinson G; Irvine J; Brown L; Murphy KJ; Stewart DS; Styra R; Wang C; Mullen M; Cole D; Rosen B
    Gynecol Oncol; 1999 Sep; 74(3):331-7. PubMed ID: 10479489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing.
    Gleeson M; Meiser B; Barlow-Stewart K; Trainer AH; Tucker K; Watts KJ; Friedlander M; Kasparian N
    Oncol Nurs Forum; 2013 May; 40(3):275-83. PubMed ID: 23619104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Symptomization and triggering processes: ovarian cancer patients' narratives on pre-diagnostic sensation experiences and the initiation of healthcare seeking.
    Brandner S; Müller-Nordhorn J; Stritter W; Fotopoulou C; Sehouli J; Holmberg C
    Soc Sci Med; 2014 Oct; 119():123-30. PubMed ID: 25179810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Familial cancer of the ovary. A family with 6 index cases].
    de Meeus JB; Bennouna C; Maréchaud M; Plocoste V; Magnin G
    J Gynecol Obstet Biol Reprod (Paris); 1993; 22(7):749-56. PubMed ID: 8308201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer.
    Andersen MR; Peacock S; Nelson J; Wilson S; McIntosh M; Drescher C; Urban N
    Gynecol Oncol; 2002 Apr; 85(1):3-8. PubMed ID: 11925113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The choice is yours? How women with ovarian cancer make sense of treatment choices.
    Ziebland S; Evans J; McPherson A
    Patient Educ Couns; 2006 Sep; 62(3):361-7. PubMed ID: 16876377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Register first, report later.
    Brean A
    Tidsskr Nor Laegeforen; 2021 Jun; 141(10):. PubMed ID: 34182718
    [No Abstract]   [Full Text] [Related]  

  • 55. [Register, learn and improve].
    Brean A
    Tidsskr Nor Laegeforen; 2020 Oct; 140(15):. PubMed ID: 33118763
    [No Abstract]   [Full Text] [Related]  

  • 56. The Register.
    Cin. Ed.
    Dent Regist; 1849 Jul; 2(4):205. PubMed ID: 33694429
    [No Abstract]   [Full Text] [Related]  

  • 57. The 2d No of the Register.
    Cin. Ed.
    Dent Regist; 1848 Jan; 1(2):108-109. PubMed ID: 33694470
    [No Abstract]   [Full Text] [Related]  

  • 58. The First No. of the Register.
    Dent Regist; 1847 Oct; 1(1):51-52. PubMed ID: 33694479
    [No Abstract]   [Full Text] [Related]  

  • 59. The Second No. of the Register.
    Dent Regist; 1847 Oct; 1(1):52. PubMed ID: 33694483
    [No Abstract]   [Full Text] [Related]  

  • 60. The "Register".
    Dent Regist; 1898 Jan; 52(1):49-50. PubMed ID: 33701298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.